Haemonetics Corporation

Day range

$115.49 – $119.20

Open

$115.50

Prev close

$116.16

Volume

777.38K

Market cap

$5.28B

Shares out

45.5M

P/E

54.89

P/S

3.91

P/B

6.31

P/FCF

21.55

ROE

11.5%

ROA

4.1%

Debt/Equity

1.40

Div yield

0.00%

As of Oct 22, 2026

• Investor communicationsOct 8, 2026

  CSL has informed the Company that it currently anticipates that the transition to the Company's devices and disposables will occur at all of CSL's current U.S. plasma collection centers. The scope and timing of the rollout remain subject to change consistent with the terms of the supply agreement, and the implementation details for the rollout are still to be determined by CSL and the Company.

• Shareholder meetingsJul 28, 2026

  The 2026 annual meeting of shareholders of Haemonetics Corporation (the "Company") was held on Friday, July 24, 2026. Of the 45,445,983 shares outstanding and entitled to vote at the meeting, 42,051,106 shares were represented at the meeting, constituting a quorum of 92.53%. The results of the votes for each proposal considered at the meeting are set forth below: [including director elections, say-on-pay vote, auditor ratification, and plan amendments]

• Business developmentsJun 5, 2026

  On June 5, 2026, Haemonetics Corporation issued a press release announcing changes to its reportable segment structure to better align external financial reporting with how the Company manages its business and allocates resources. Beginning with the first quarter of fiscal 2027, the previously reported Plasma and Blood Center segments will be combined into a single reportable segment, Apheresis, while the Hospital segment will be renamed MedSurg.

• Board of directorsMay 1, 2026

  Charles J. Dockendorff informed Haemonetics Corporation that he will not stand for re-election at the Company's 2026 Annual Meeting of Shareholders. Mr. Dockendorff has served as a member of the Board of Directors of the Company since 2014 and currently serves as a member of the Audit Committee and the Governance and Compliance Committee.

• Debt activityMar 3, 2026

  On March 2, 2026, Haemonetics Corporation (the "Company") repaid in full at maturity its outstanding 0.00% Convertible Senior Notes due 2026 (the "Notes"). The Company paid an aggregate amount of $300,000,000 in cash, representing the outstanding principal amount of the Notes.

• PODDInsulet Corporation+0.60%
• DXCMDexCom, Inc.-0.48%
• QTRXQuanterix Corporation Common Stock+0.70%
• SIBNSI-BONE, Inc. Common Stock-0.37%
• PENPenumbra, Inc.-0.17%
• ZBHZimmer Biomet Holdings, Inc.-0.25%
• LNTHLantheus Holdings, Inc-0.30%
• HQYHealthEquity, Inc+2.97%

Days to cover

5.3

Short interest

3.04M

Avg volume

569.32K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Haemonetics Gains 149.3% in a Year: What's Driving the Rally?
  positiveZacks Investment Research· Oct 16, 2026
• Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term
  positiveZacks Investment Research· Oct 13, 2026
• Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength?
  neutralZacks Investment Research· Oct 9, 2026
• PAHC vs. HAE: Which Stock Should Value Investors Buy Now?
  positiveZacks Investment Research· Sep 18, 2026
• GEHC vs. HAE: Which Stock Is the Better Value Option?
  positiveZacks Investment Research· Aug 31, 2026